A biopharmaceutical company focused on the development and commercialization of drugs to treat metabolic diseases, endocrine disorders and oncology within niche markets that have unmet medical needs.


Updates from The Motley Fool

Latest updates on Insmed from Fool.com.


Stock Performance

INSM vs. S&P 500 | 2 Year Performance
View Interactive INSM Charts
Sponsored by

Key Data Points

Primary metrics and data points about Insmed.
Current Price: $12.68
Prev Close: $13.41
Open: $13.37
Bid: $8.12
Ask: $12.75
Day's Range: $12.52 - $13.88
52wk Range: $9.02 - $26.66
Volume: 384,085
Avg Vol 325,288
Market Cap: $783.67M
P/E (ttm): -6.27
EPS (ttm): -$2.14
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Insmed.
CAPS Rating 2 out of 5
 
82 Outperform
13 Underperform
CAPS All Stars
 
15 Outperform
8 Underperform

How do you think Insmed will perform against the market?



You pick for Insmed is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Will Lewis, CEO

100% Approve

Based on 2 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Insmed.

A biopharmaceutical company focused on the development and commercialization of drugs to treat metabolic diseases, endocrine disorders and oncology within niche markets that have unmet medical needs.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers